PREZISTA 400 MG Israel - English - Ministry of Health

prezista 400 mg

j-c health care ltd - darunavir as ethanolate - film coated tablets - darunavir as ethanolate 400 mg - darunavir - darunavir - prezista , co-administered with 100 mg ritonavir (prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (hiv-1) infection for over 18 years of age.

PREZISTA 600 MG Israel - English - Ministry of Health

prezista 600 mg

j-c health care ltd - darunavir as ethanolate - film coated tablets - darunavir as ethanolate 600 mg - darunavir - darunavir - prezista , co-administered with 100 mg ritonavir (prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (hiv-1) infection for over 18 years of age.

EMTRIVA emtricitabine 200mg capsule blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

emtriva emtricitabine 200mg capsule blister pack

gilead sciences pty ltd - emtricitabine, quantity: 200 mg - capsule, hard - excipient ingredients: crospovidone; povidone; microcrystalline cellulose; magnesium stearate; propylene glycol; purified water; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; indigo carmine; potable water; gelatin; sodium lauryl sulfate - emtriva is indicated for the treatment of hiv in combination with other antiretroviral agents in adults and paediatric patients 12 years of age and older, weighing more than 33 kg. evidence to support this claim is based on surrogate markers (plasma hiv rna and cd4 count) in antiretroviral naive individuals and in antiretroviral experienced individuals with virological suppression (see clinical trials).

EMTRIVA emtricitabine 200mg capsule bottle Australia - English - Department of Health (Therapeutic Goods Administration)

emtriva emtricitabine 200mg capsule bottle

gilead sciences pty ltd - emtricitabine, quantity: 200 mg - capsule, hard - excipient ingredients: magnesium stearate; microcrystalline cellulose; povidone; crospovidone; titanium dioxide; indigo carmine; potable water; gelatin; sodium lauryl sulfate; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; purified water; ethanol; strong ammonia solution; potassium hydroxide; iron oxide black - emtriva is indicated for the treatment of hiv in combination with other antiretroviral agents in adults and paediatric patients 12 years of age and older, weighing more than 33 kg. evidence to support this claim is based on surrogate markers (plasma hiv rna and cd4 count) in antiretroviral naive individuals and in antiretroviral experienced individuals with virological suppression (see clinical trials).

PREZCOBIX darunavir/cobicistat 800 mg/150 mg film coated tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

prezcobix darunavir/cobicistat 800 mg/150 mg film coated tablet bottle

janssen-cilag pty ltd - darunavir, quantity: 800 mg; cobicistat, quantity: 150 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; silicon dioxide; magnesium stearate; hypromellose; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - prezcobix, a fixed dose combination of darunavir and cobicistat, is indicated in combination with other antiretroviral agents for the treatment of adult patients with human immunodeficiency virus- 1 (hiv-1) infection in:,- antiretroviral treatment-naive patients,- antiretroviral treatment-experienced patients with no darunavir resistance associated mutations and who have plasma hiv-1 rna <100,000 copies/ml,- antiretroviral treatment-experienced but hiv protease inhibitor-naive patients for whom hiv-1 genotype testing is unavailable (see section 4.2 dose and method of administration)

TELZIR fosamprenavir 700mg (as calcium) tablet Australia - English - Department of Health (Therapeutic Goods Administration)

telzir fosamprenavir 700mg (as calcium) tablet

viiv healthcare pty ltd - fosamprenavir calcium, quantity: 853.2 mg (equivalent: fosamprenavir, qty 700 mg) - tablet, film coated - excipient ingredients: povidone; croscarmellose sodium; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; titanium dioxide; hypromellose; triacetin; iron oxide red - telzir, in combination with low dose ritonavir, is indicated for the treatment of human immunodeficiency virus type 1 (hiv-1) infected adults, adolescents and children of 6 years and above in combination with other antiretroviral medicinal products. in antiretroviral experienced adults telzir in combination with low dose ritonavir has not been shown to be as effective as lopinavir/ritonavir. no comparative studies have been undertaken in children or adolescents.

EDURANT FILM-COATED TABLET 25 MG Singapore - English - HSA (Health Sciences Authority)

edurant film-coated tablet 25 mg

johnson & johnson international (singapore) pte ltd - rilpivirine hydrochloride 27.50 mg eqv rilpivirine - tablet, film coated - 25 mg - rilpivirine hydrochloride 27.50 mg eqv rilpivirine 25 mg

INTELENCE TABLET 100MG Singapore - English - HSA (Health Sciences Authority)

intelence tablet 100mg

johnson & johnson international (singapore) pte ltd - etravirine - tablet - 100mg - etravirine 100mg

INTELENCE TABLET 200 MG Singapore - English - HSA (Health Sciences Authority)

intelence tablet 200 mg

johnson & johnson international (singapore) pte ltd - etravirine - tablet - 200mg/tablet - etravirine 200mg/tablet

REZOLSTA Israel - English - Ministry of Health

rezolsta

j-c health care ltd - cobicistate; darunavir as ethanolate - film coated tablets - cobicistate 150 mg; darunavir as ethanolate 800 mg - darunavir - rezolsta is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv 1) infection in treatment-naïve and treatment-experienced adults with no darunavir resistance-associated substitutions (v11i, v32i, l33f, i47v, i50v, i54l, i54m, t74p, l76v, i84v, l89v).שינוי משטר מינון 2/4/2019pregnancy and postpartumtreatment with rezolsta during pregnancy results in low darunavir exposure (see sections 4.4 and 5.2). therefore, therapy with rezolsta should not be initiated during pregnancy, and women who become pregnant during therapy with rezolsta should be switched to an alternative regimen, see section 4.4 and 4.6. darunavir/ritonavir may be considered as an alternative.